DGAP-News: Eckert&Ziegler to become the long-term contrast agent supplier to leading Polish clinic chain - new production location in Warsaw being planned
(firmenpresse) - DGAP-News: Eckert&Ziegler Strahlen- und Medizintechnik AG / Key
word(s): Contract
Eckert&Ziegler to become the long-term contrast agent supplier to
leading Polish clinic chain - new production location in Warsaw being
planned
02.03.2011 / 11:18
---------------------------------------------------------------------
Berlin, 2 March 2011. Eckert&Ziegler Strahlen- und Medizintechnik AG
(ISIN DE0005659700), a specialist in the production of radioactive contrast
agents for cancer detection, has concluded a long-term contract with
Euromedic International B.V., based in Budapest, to supply Polish
diagnostics centres. The framework agreement for so-called FDG
(Fluorodeoxyglucose (18 F)) also envisages the creation of a pharmaceutical
production facility in Warsaw in addition to the FDG supply.
Eckert&Ziegler radiopharmacy Director, Dr. AndréHeßand Axel Schmidt,
Managing Director of the group subsidiary Eckert&Ziegler f-con
Deutschland GmbH that manages the project, declared in a joint statement:
'Euromedic is a strategic partner with whom we have already been
successfully cooperating for many years. We support the further expansion
of the Polish cancer treatment centres with the creation of a new
radiodiagnostics production plant near Warsaw and are looking forward to
closer cooperation with Euromedic. It enables us to further expand our
industry leadership in Germany to Eastern Europe.'
FDG will be used within the framework of positron emission tomography (PET)
for the safe and early detection of even the smallest tumor foci. As a
result of its short half-life, FDG has to be produced daily on locally
cited cyclotrons and delivered to the clinics as soon as possible. Eckert&Ziegler currently supplies a host of Polish PET-CT centres from its
production facility in Berlin.
Eckert&Ziegler has several radiopharmaceutical production locations in
Germany and in addition to Fluor-18 based radiodiagnostics for nuclear
medical imaging (PET), also markets the licensed product Yttriga, a
precursor agent used in radiolabeling for the production of numerous
radiotherapeutics. Eckert&Ziegler additionally supplies nuclear medical
facilities with synthesis technology and Gallium-68 (PET) radionuclide
generators worldwide.
About Eckert&Ziegler: Eckert&Ziegler Strahlen- und Medizintechnik AG is
an isotope technology company which operates worldwide and is the holding
company for a host of specialised subsidiaries engaged in the processing of
radioisotopes as well as the development, production and the sales of
isotope technical components, medical technical devices and related
products. The group of companies has 550 employees worldwide and is among
the largest providers of radioactive components for radiation therapy and
nuclear medicine. You can find further information about Eckert&Ziegler
under www.ezag.de.
About Euromedic: Euromedic is one of the largest and most successful
providers of medical services in Europe. The company specialises in
diagnostic examinations, dialysis and teleradiology and has more than 6000
employees in 207 medical centres. After almost two decades in the service
of high-quality medical care, Euromedic has re-defined the relationship
between privately financed health care and the public sector. The company
provides life-saving medical services, within the existing, publicly
managed health care system. The company has been engaged in Poland since
2000 where it operates 19 dialysis centres as well as 18 diagnostics
centres, among these are three PET-CT locations in Wroclaw, Warsaw and
Poznan. You can find further information about Euromedic under
www.euromedic.com.
Your contact in case you have any further questions:
Eckert&Ziegler AG, Karolin Riehle, Public Relations
Robert-Rössle-Str. 10, D-13125 Berlin
Tel.: +49 (0) 30 / 941084-138, Fax-112
E-Mail: karolin.riehle(at)ezag.de, www.ezag.de
End of Corporate News
---------------------------------------------------------------------
02.03.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Eckert&Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle(at)ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, Düsseldorf, Hamburg, München
End of News DGAP News-Service
---------------------------------------------------------------------
114138 02.03.2011
Datum: 02.03.2011 - 11:18 Uhr
Sprache: Deutsch
News-ID 33355
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 213 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Eckert&Ziegler to become the long-term contrast agent supplier to leading Polish clinic chain - new production location in Warsaw being planned"
steht unter der journalistisch-redaktionellen Verantwortung von
Eckert&Ziegler Strahlen- und Medizintechnik AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
